Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials

Sahebkar, A. and Simental-Mendía, L. E. and Pirro, M. and Banach, M. and Watts, G. F. and Sirotri, C. and Al-Rasadi, K. and Atkin, S. L. (2018) Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Scientific Reports, 8 (1).

[img] Text
Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins a systematic review and meta-analysis of randomized controlled trials.pdf

Download (2MB)

Abstract

The aim of this meta-analysis of randomized placebo-controlled clinical trials was to assess the effect of ezetimibe on plasma lipoprotein(a) concentrations. Only randomized placebo-controlled trials investigating the impact of ezetimibe treatment on cholesterol lowering that include lipoprotein(a) measurement were searched in PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases (from inception to February 26th, 2018). A random-effects model and generic inverse variance method were used for quantitative data synthesis. Sensitivity analysis was conducted using the leave-one-out method. A weighted random-effects meta-regression was performed to evaluate the impact of potential confounders on lipoprotein concentrations. This meta-analysis of data from 10 randomized placebo-controlled clinical trials (15 treatment arms) involving a total of 5188 (3020 ezetimibe and 2168 control) subjects showed that ezetimibe therapy had no effect on altering plasma Lp(a) concentrations (WMD: −2.59, 95 CI: −8.26, 3.08, p = 0.370; I2 = 88.71, p(Q) < 0.001). In the subgroup analysis, no significant alteration in plasma Lp(a) levels was observed either in trials assessing the impact of monotherapy with ezetimibe versus placebo (WMD: −4.64, 95 CI: −11.53, 2.25, p = 0.187; I2 = 65.38, p(Q) = 0.005) or in trials evaluating the impact of adding ezetimibe to a statin versus statin therapy alone (WMD: −1.04, 95 CI: −6.34, 4.26, p = 0.700; I2 = 58.51, p(Q) = 0.025). The results of this meta-analysis suggest that ezetimibe treatment either alone or in combination with a statin does not affect plasma lipoprotein(a) levels. © 2018, The Author(s).

Item Type: Article
Additional Information: Cited By :2 Export Date: 16 February 2020 Correspondence Address: Sahebkar, A.; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical SciencesIran; email: saheb2000@yahoo.com
Uncontrolled Keywords: ezetimibe hydroxymethylglutaryl coenzyme A reductase inhibitor hypocholesterolemic agent lipoprotein A placebo adult aged blood chemistry combination drug therapy female human hypercholesterolemia male meta analysis middle aged plasma randomized controlled trial (topic) treatment outcome very elderly young adult Aged, 80 and over Anticholesteremic Agents Drug Therapy, Combination Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Lipoprotein(a) Placebos Randomized Controlled Trials as Topic
Subjects: QV pharmacology
QW Microbiology and Immunology
Divisions: Mashhad University of Medical Sciences
Depositing User: lib2 lib2 lib2
Date Deposited: 04 May 2020 08:34
Last Modified: 04 May 2020 08:34
URI: http://eprints.mums.ac.ir/id/eprint/17511

Actions (login required)

View Item View Item